Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Furiex Pharmaceuticals Inc FURX

Healthcare Drug Manufacturers - Specialty & Generic

Recent & Breaking News (NDAQ:FURX)

SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.

Business Wire April 28, 2014

Furiex Pharmaceuticals, Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover

PR Newswire April 28, 2014

Furiex Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Forest Laboratories

Business Wire April 28, 2014

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. - FURX

PR Newswire April 28, 2014

Furiex Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Forest Laboratories, Inc.

PR Newswire April 28, 2014

SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Furiex Pharmaceuticals, Inc. - FURX

PR Newswire April 28, 2014

FURIEX INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Furiex Pharmaceuticals, Inc. (FURX) Over the Proposed Sale of the Company to Forest Laboratories, Inc.

Business Wire April 28, 2014

INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of Furiex Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Forest Laboratories, Inc.

Business Wire April 28, 2014

FURIEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Business Wire April 28, 2014

Newman Ferrara LLP Announces Investigation of Furiex Pharmaceuticals, Inc.

Business Wire April 28, 2014

FURIEX ALERT: Proposed Buyout of Furiex Pharmaceuticals under Investigation by Johnson & Weaver, LLP

Business Wire April 28, 2014

Furiex Pharmaceuticals (FURX) Shareholder Alert - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Furiex Pharmaceuticals, Inc.

PR Newswire April 28, 2014

Furiex - Investor Alert - Tripp Levy Pllc Seeks Higher Price For Shareholders

PR Newswire April 28, 2014

Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)

Business Wire April 28, 2014

Furiex Pharmaceuticals Announces First Quarter 2014 Earnings Release and Conference Call

Business Wire April 7, 2014

Furiex Pharmaceuticals Announces Acceptance to Late-Breaking Abstract Session at Digestive Disease Week 2014

Business Wire April 3, 2014

Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data from the EXAMINE Trial at the American College of Cardiology's 63rd Annual Scientific Session

Business Wire March 27, 2014

Furiex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results

Business Wire March 11, 2014

Furiex Pharmaceuticals Confirms Takeda's Submission of a New Drug Application for Trelagliptin Succinate (SYR-472) in Japan for the Treatment of Type 2 Diabetes

Business Wire March 7, 2014

Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release and Conference Call

Business Wire February 10, 2014